Dry eye disease affects the ocular surface and is characterized by dryness, inflammation, pain, discomfort, and irritation. Dry eye is a complex, multi-factorial disease that can occurs differently in patients, is affected by age. Due to the prevalence of the disease, well over one billion dollars are spent on treatment of the disease each year in the United States alone (IMS Health, 2014). One cause of the disease is inflammation of the ocular surface resulting from a patient’s immune response. Although physicians may prescribe topical steroid eye drops for the treatment of dry eye disease, chronic use of topical steroids can lead to elevations in intraocular pressure, which is a risk factor for glaucoma. Conversely, patients often do not reliably self-administer these drops, which can lead to eye irritation and continual, if not more, inflammation.
Eximore is developing a product currently undergoing in-vivo experiments